Cell and Gene Therapy Market Research Report Information by Therapy Type (Cell Therapy and Gene Therapy), Application (Cancer, Neurological Disorders, Cardiovascular Disorders, Rare Diseases, Ophthalmology, Blood Disorders and Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 Data Mining Process

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 Secondary Research data flow:

3.5 PRIMARY RESEARCH:

3.5.1 Primary Research DATA FLOW:

3.5.2 Primary Research: Number of Interviews conducted

3.5.3 Primary Research: Regional Coverage

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 Revenue Analysis Approach

3.7 DATA FORECASTING

3.7.1 Data forecasting Type

3.8 DATA MODELING

3.8.1 microeconomic factor analysis:

3.8.2 Data modeling:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 Growing incidences of Cancer and rare disorders

4.2.2 Increasing approval for Gene and Cell therapy Products

4.3 RESTRAINTS

4.3.1 Clinical Trial Failure associated with gene and cell therapy

4.4 OPPORTUNITY

4.4.1 Growing investment in the field of gene and cell therapy

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL

5.1.1 Threat of New Entrants

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 Threat of Substitutes

5.1.4 Bargaining Power of Buyers

5.1.5 Intensity of Rivalry

5.2 IMPACT OF COVID-19 ON THE GLOBAL CELL AND GENE THERAPY MARKET

6 GLOBAL CELL AND GENE THERAPY MARKET, BY THERAPY TYPE

6.1 OVERVIEW

6.2 CELL THERAPY

6.2.1 Autologous

6.2.2 Allogeneic

6.3 GENE THERAPY

6.3.1 Ex vivo

6.3.2 In vivo

7 GLOBAL CELL AND GENE THERAPY MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 CANCER

7.3 NEUROLOGICAL DISORDERS

7.4 CARDIOVASCULAR DISORDERS

7.5 RARE DISEASES

7.6 OPHTHALMOLOGY

7.7 BLOOD DISORDERS

7.8 OTHERS

8 GLOBAL CELL AND GENE THERAPY MARKET, BY REGION

8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 Germany

8.3.2 France

8.3.3 UK

8.3.4 Italy

8.3.5 Spain

8.3.6 Rest of Europe

8.4 ASIA-PACIFIC

8.4.1 China

8.4.2 India

8.4.3 Japan

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-pacific

8.5 REST OF THE WORLD

8.5.1 Middle East & Africa

8.5.2 South America

9 COMPETITIVE LANDSCAPE

9.1 INTRODUCTION

9.2 MARKET SHARE ANALYSIS, 2022

9.3 COMPETITOR DASHBOARD

9.4 PUBLIC PLAYERS STOCK SUMMARY

9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 product launch / Product approval

9.6.2 Collaboration

9.6.3 Agreement

9.6.4 Expansion

10 COMPANY PROFILES

10.1 NOVARTIS AG

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 products OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 BRISTOL-MYERS SQUIBB COMPANY

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 products OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 AMGEN INC.

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 productS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 AURION BIOTECH

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 productS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 KEY STRATEGIES

10.5 SAREPTA THERAPEUTICS, INC.

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 productS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 FERRING B.V.

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 products OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 SIBIONO GENETECH CO. LTD., SHENZHEN (SIBIONO)

10.7.1 COMPANY OVERVIEW

10.7.2 products OFFERED

10.7.3 KEY DEVELOPMENTS

10.7.4 KEY STRATEGIES

10.8 BLUEBIRD BIO, INC.

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 SWOT Analysis

10.8.6 KEY STRATEGIES

10.9 KITE PHARMACEUTICALS, INC.

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 SWOT Analysis

10.9.6 KEY STRATEGIES

10.10 JANSSEN GLOBAL SERVICES

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 Products OFFERed

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT

TABLE 2 MAJOR CELL AND GENE THERAPY APPROVED PRODUCTS

TABLE 3 GLOBAL CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 4 GLOBAL CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY REGION, 2021–2032 (USD MILLION)

TABLE 5 GLOBAL CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 6 GLOBAL CELL AND GENE THERAPY MARKET, FOR AUTOLOGOUS, BY REGION, 2021–2032 (USD MILLION)

TABLE 7 GLOBAL CELL AND GENE THERAPY MARKET, FOR ALLOGENEIC, BY REGION, 2021–2032 (USD MILLION)

TABLE 8 GLOBAL CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY REGION, 2021–2032 (USD MILLION)

TABLE 9 GLOBAL CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 10 GLOBAL CELL AND GENE THERAPY MARKET, FOR EX VIVO, BY REGION, 2021–2032 (USD MILLION)

TABLE 11 GLOBAL CELL AND GENE THERAPY MARKET, FOR IN VIVO, BY REGION, 2021–2032 (USD MILLION)

TABLE 12 GLOBAL CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 13 GLOBAL CELL AND GENE THERAPY MARKET, FOR CANCER, BY REGION, 2021–2032 (USD MILLION)

TABLE 14 GLOBAL CELL AND GENE THERAPY MARKET, FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 15 GLOBAL CELL AND GENE THERAPY MARKET, FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 16 GLOBAL CELL AND GENE THERAPY MARKET, FOR RARE DISEASES, BY REGION, 2021–2032 (USD MILLION)

TABLE 17 GLOBAL CELL AND GENE THERAPY MARKET, FOR OPHTHALMOLOGY, BY REGION, 2021–2032 (USD MILLION)

TABLE 18 GLOBAL CELL AND GENE THERAPY MARKET, FOR BLOOD DISORDERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 19 GLOBAL CELL AND GENE THERAPY MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 20 GLOBAL CELL AND GENE THERAPY MARKET, BY REGION, 2019–2032 (USD MILLION)

TABLE 21 NORTH AMERICA: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 22 NORTH AMERICA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 23 NORTH AMERICA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 24 NORTH AMERICA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 25 NORTH AMERICA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 26 US: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 27 US: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 28 US: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 29 US: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 30 CANADA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 31 CANADA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 32 CANADA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 33 CANADA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 34 EUROPE: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 35 EUROPE: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 36 EUROPE: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 37 EUROPE: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 38 EUROPE: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 39 GERMANY: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 40 GERMANY: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 41 GERMANY: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 42 GERMANY: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 43 FRANCE: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 44 FRANCE: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 45 FRANCE: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 46 FRANCE: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 47 UK: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 48 UK: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 49 UK: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 50 UK: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 51 ITALY: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 52 ITALY: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 53 ITALY: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 54 ITALY: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 55 SPAIN: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 56 SPAIN: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 57 SPAIN: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 58 SPAIN: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 59 REST OF EUROPE: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 60 REST OF EUROPE: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 61 REST OF EUROPE: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 62 REST OF EUROPE: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 63 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 64 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 65 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 66 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 67 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 68 CHINA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 69 CHINA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 70 CHINA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 71 CHINA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 72 INDIA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 73 INDIA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 74 INDIA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 75 INDIA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 76 JAPAN: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 77 JAPAN: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 78 JAPAN: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 79 JAPAN: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 80 AUSTRALIA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 81 AUSTRALIA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 82 AUSTRALIA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 83 AUSTRALIA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 84 SOUTH KOREA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 85 SOUTH KOREA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 86 SOUTH KOREA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 87 SOUTH KOREA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 88 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 89 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 90 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 91 REST OF ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 92 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, BY REGION, 2019–2032 (USD MILLION)

TABLE 93 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 94 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 95 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 96 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 97 MIDDLE EAST & AFRICA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 98 MIDDLE EAST & AFRICA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 99 MIDDLE EAST & AFRICA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 100 MIDDLE EAST & AFRICA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 101 SOUTH AMERICA: CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2019–2032 (USD MILLION)

TABLE 102 SOUTH AMERICA: CELL AND GENE THERAPY MARKET, FOR CELL THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 103 SOUTH AMERICA: CELL AND GENE THERAPY MARKET, FOR GENE THERAPY, BY TYPE, 2019–2032 (USD MILLION)

TABLE 104 SOUTH AMERICA: CELL AND GENE THERAPY MARKET, BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 105 PUBLIC PLAYERS STOCK SUMMARY

TABLE 106 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

TABLE 107 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 108 COLLABORATION

TABLE 109 AGREEMENT

TABLE 110 EXPANSION

TABLE 111 NOVARTIS AG: PRODUCT OFFERED

TABLE 112 NOVARTIS AG.: KEY DEVELOPMENTS

TABLE 113 BRISTOL-MYERS SQUIBB COMPANY.: PRODUCT OFFERED

TABLE 114 BRISTOL-MYERS SQUIBB COMPANY.: KEY DEVELOPMENTS

TABLE 115 AMGEN INC.: PRODUCT OFFERED

TABLE 116 AURION BIOTECH: PRODUCT OFFERED

TABLE 117 AURION BIOTECH: KEY DEVELOPMENTS

TABLE 118 SAREPTA THERAPEUTICS, INC.: PRODUCT OFFERED

TABLE 119 SAREPTA THERAPEUTICS, INC.: KEY DEVELOPMENTS

TABLE 120 FERRING B.V.: PRODUCT OFFERED

TABLE 121 FERRING B.V.: KEY DEVELOPMENTS

TABLE 122 SIBIONO GENETECH CO. LTD., SHENZHEN (SIBIONO).: PRODUCT OFFERED

TABLE 123 BLUEBIRD BIO, INC.: PRODUCTS OFFERED

TABLE 124 BLUEBIRD BIO, INC.: KEY DEVELOPMENTS

TABLE 125 KITE PHARMACEUTICALS, INC.: PRODUCTS OFFERED

TABLE 126 JANSSEN GLOBAL SERVICES: PRODUCTS OFFERED

TABLE 127 JANSSEN GLOBAL SERVICES: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL CELL AND GENE THERAPY MARKET: STRUCTURE

FIGURE 2 GLOBAL CELL AND GENE THERAPY MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)

FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL CELL AND GENE THERAPY MARKET

FIGURE 6 GLOBAL CELL AND GENE THERAPY MARKET; THERAPY TYPE SEGMENT ATTRACTIVENESS, (USD MILLION)

FIGURE 7 GLOBAL CELL AND GENE THERAPY MARKET, BY THERAPY TYPE, 2023 & 2032 (USD MILLION)

FIGURE 8 GLOBAL CELL AND GENE THERAPY MARKET SHARE (%), BY THERAPY TYPE, 2022

FIGURE 9 GLOBAL CELL AND GENE THERAPY MARKET; APPLICATION SEGMENT ATTRACTIVENESS, (USD MILLION)

FIGURE 10 GLOBAL CELL AND GENE THERAPY MARKET, BY APPLICATION, 2023 & 2032 (USD MILLION)

FIGURE 11 GLOBAL CELL AND GENE THERAPY MARKET SHARE (%), BY APPLICATION, 2022

FIGURE 12 GLOBAL CELL AND GENE THERAPY MARKET, BY REGION, 2022 & 2032 (USD MILLION)

FIGURE 13 GLOBAL CELL AND GENE THERAPY MARKET SHARE (%), BY REGION, 2022

FIGURE 14 NORTH AMEICA MARKET ANALYSIS: CELL AND GENE THERAPY MARKET, 2019-2032 (USD MILLION)

FIGURE 15 NORTH AMERICA: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)

FIGURE 16 NORTH AMERICA: CELL AND GENE THERAPY MARKET SHARE (%), BY COUNTRY, 2022

FIGURE 17 EUROPE MARKET ANALYSIS: CELL AND GENE THERAPY MARKET, 2019-2032 (USD MILLION)

FIGURE 18 EUROPE: CELL AND GENE THERAPY MARKET, BY REGION, 2022 & 2032 (USD MILLION)

FIGURE 19 EUROPE: CELL AND GENE THERAPY MARKET SHARE (%), BY REGION, 2022

FIGURE 20 ASIA-PACIFIC MARKET ANALYSIS: CELL & GENE THERAPY MARKET, 2019-2032 (USD MILLION)

FIGURE 21 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)

FIGURE 22 ASIA-PACIFIC: CELL AND GENE THERAPY MARKET SHARE (%), BY COUNTRY, 2022

FIGURE 23 REST OF THE WORLD MARKET ANALYSIS: CELL AND GENE THERAPY MARKET, 2019-2032 (USD MILLION)

FIGURE 24 REST OT THE WORLD: CELL AND GENE THERAPY MARKET, BY REGION, 2022 & 2032 (USD MILLION)

FIGURE 25 REST OT THE WORLD: CELL AND GENE THERAPY MARKET SHARE (%), BY REGION, 2022

FIGURE 26 CELL AND GENE THERAPY MARKET PLAYERS: COMPETITIVE ANALSIS, 2022

FIGURE 27 COMPETITOR DASHBOARD: GLOBAL CELL AND GENE THERAPY MARKET

FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 NOVARTIS AG.: SWOT ANALYSIS

FIGURE 30 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 BRISTOL-MYERS SQUIBB COMPANY.: SWOT ANALYSIS

FIGURE 32 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 SAREPTA THERAPEUTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 FERRING B.V.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 FERRING B.V.: SWOT ANALYSIS

FIGURE 36 BLUEBIRD BIO, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 BLUEBIRD BIO, INC.: SWOT ANALYSIS

FIGURE 38 KITE PHARMACEUTICALS, INC.: SWOT ANALYSIS